Page last updated: 2024-08-21

pyrazines and Myelomonocytic Leukemia, Chronic

pyrazines has been researched along with Myelomonocytic Leukemia, Chronic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buda, G; Canestraro, M; Fazzi, R; Galimberti, S; Guerrini, F; Khan, R; Maffei, R; Marasca, R; Orciuolo, E; Petrini, M	1

Other Studies

1 other study(ies) available for pyrazines and Myelomonocytic Leukemia, Chronic

Article	Year
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. Leukemia, 2008, Volume: 22, Issue:3 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Hydroxamic Acids; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Chronic; Megakaryocytes; Neoplasm Proteins; Pyrazines; Vorinostat; WT1 Proteins	2008

Article

Year

Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.

Leukemia, 2008, Volume: 22, Issue:3

Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Hydroxamic Acids; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Chronic; Megakaryocytes; Neoplasm Proteins; Pyrazines; Vorinostat; WT1 Proteins

2008